NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
13 hedge funds and large institutions have $5.66M invested in NKGen Biotech, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
44% more funds holding
Funds holding: 9 → 13 (+4)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
59% less capital invested
Capital invested by funds: $13.7M → $5.66M (-$8.01M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$103K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$32.5K |
| 3 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$30.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$21.3K |
| 5 |
TCM
Towneley Capital Management
Laguna Hills,
California
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
-$4.61M |
| 2 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$747K |
| 3 |
Millennium Management
New York
|
-$50.6K |
NKGN Hedge Fund Activity: Q1 2024 in Review
13 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q1 2024, worth a combined $5.66M — down 59% from $13.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NKGN positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $103K. The largest seller was Sandia Investment Management, exiting entirely with an estimated $4.61M sold.
- 13 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q1 2024, up from 9 in Q4 2023.
- Funds reported $5.66M of NKGen Biotech, Inc. Common Stock stock for Q1 2024, down 59% quarter-over-quarter.
- 6 funds opened new NKGen Biotech, Inc. Common Stock positions in Q1 2024 and 2 closed out, a net change of +4 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q1 2024 was Vanguard Group, an estimated $103K added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q1 2024 was Sandia Investment Management, an estimated $4.61M sold.
Based on aggregated 13F filings for Q1 2024.